Plural Ring Nitrogens In The Hexacyclo Ring System (e.g., Reserpic Acid Lactone, Etc.) Patents (Class 546/40)
-
Publication number: 20150094324Abstract: The present disclosure is concerned with a process for the preparation of the above disclosed compounds, pharmaceutically acceptable salts thereof, deuterated forms thereof, isomers thereof, solvates thereof, or mixtures thereof which comprises subjecting a 17-substituted-3,14-dihydroxypyridomorphinan to dialkylation at the phenolic hydroxyl at the 3-position and the tertiary alcohol at the 14-position followed by selective dealkylation of the phenolic ether function.Type: ApplicationFiled: May 2, 2013Publication date: April 2, 2015Inventor: Subramaniam Ananthan
-
Patent number: 8952030Abstract: A morphinan derivative represented by the following general formula (I): (in the formula, R1 represents hydrogen, C1-6 alkyl, cycloalkylalkyl (the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms), aralkyl (the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms) and the like, R2 represents hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, aralkyl (the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms) and the like, R3, R4 and R5 represent hydrogen, hydroxy, carbamoyl, C1-6 alkoxy, C6-10 aryloxy and the like, R6a, R6b, R7, R8, R9, and R10 represent hydrogen and the like, X represents O or CH2, and Y represents C?O, SO2, an atomic bond and the like), or an acid addition salt thereof is used as an analgesic.Type: GrantFiled: September 7, 2012Date of Patent: February 10, 2015Assignees: The Kitasato Institute, Nippon Chemiphar Co., Ltd.Inventors: Hiroshi Nagase, Hideaki Fujii, Eriko Nakata, Yoshikazu Watanabe, Toshihiro Takahashi
-
Patent number: 8952159Abstract: The present invention relates to a new amorphous form of rifaximin and to methods for the preparation thereof by means of high energy milling or Spray drying. The present invention further relates to a new amorphous form for use as medicament and to the pharmaceutical compositions composing it.Type: GrantFiled: December 27, 2010Date of Patent: February 10, 2015Inventors: Silvio Massimo Lavagna, Daniela Secci, Franco Padella
-
Publication number: 20150011767Abstract: The present invention discloses an application of koumine and homologue thereof in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like, in particular an application of Gelsemium alkaloid monomer koumine and homologue thereof or pharmaceutically acceptable salt thereof as active ingredient in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like.Type: ApplicationFiled: July 16, 2014Publication date: January 8, 2015Applicant: Fujian Medical UniversityInventors: Changxi Yu, Ying Xu, Jian Yang, Yanping Su, Hongda Cai
-
Publication number: 20140343015Abstract: A morphinan derivative represented by the following general formula (I) (in the formula, R1 represents hydrogen, C1-6 alkyl, cycloalkylalkyl (the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms), aralkyl (the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms) and the like, R2 represents hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, aralkyl (the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms) and the like, R3, R4 and R5 represent hydrogen, hydroxy, carbamoyl, C1-6 alkoxy, C6-10 aryloxy and the like, R6a, R6b, R7, R8, R9, and R10 represent hydrogen and the like, X represents O or CH2, and Y represents C?O, SO2, an atomic bond and the like), or an acid addition salt thereof is used as an analgesic.Type: ApplicationFiled: September 7, 2012Publication date: November 20, 2014Applicants: NIPPON CHEMIPHAR CO., LTD., THE KITASATO INSTITUTEInventors: Hiroshi Nagase, Hideaki Fujii, Eriko Nakata, Yoshikazu Watanabe, Toshihiro Takahashi
-
Publication number: 20140256717Abstract: There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.Type: ApplicationFiled: May 18, 2012Publication date: September 11, 2014Applicant: Centro Nacional de Investigaciones Oncológicas (CNIO)Inventors: Joaquín Pastor Fernández, Rosa Maria Álvarez Escobar, Rosario Concepción Riesco Fagundo, Ana Belén García García, Antonio Rodríguez Hergueta, Jose Ignacio Martin Hernando, Carmen Blanco Aparicio, David Álvaro Cebrián Muñoz
-
Publication number: 20140220588Abstract: The invention relates to novel fluorescent dyes with phosphorylated hydroxymethyl groups, a method for preparing the same as well as to their use in imaging techniques. The fluorescent dyes are coumarin, rhodamine or BODIPY dyes having of one of the following general formulae I-III: wherein W=OP(O) Y1Y2 or P(O) Y1Y2, where Y1 and Y2 independently denote any of the following residues: OH, O(?), ORa and ORb, NHRa and NHRb, NRaRb and NRcRd, ORa and NHRb, ORa and NRbRc, NHRa and NRbRc; and any salt thereof.Type: ApplicationFiled: October 18, 2011Publication date: August 7, 2014Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.Inventors: Stefan W. Hell, Shamil Nizamov, Gerald Donnert, Kirill Kolmakov, Heiko Schill, Lars Kastrup, Christian A. Wurm, Vladimir N. Belov, Johanna Bueckers, Katrin Willig
-
Publication number: 20140107143Abstract: Compounds of formulas: are disclosed. The compounds are useful for ameliorating the side effects of therapeutic opiates.Type: ApplicationFiled: September 27, 2013Publication date: April 17, 2014Applicant: Rensselaer Polytechnic InstituteInventor: Mark P. WENTLAND
-
Publication number: 20140012001Abstract: The present invention discloses a stable amorphous form of Rifaximin characterised by having X-ray powder diffraction pattern as given in FIG. 1, having a 2? peaks at 7.2 and having moisture content in the range of 3% to 4% preferably, 3.4% to 3.7%. This invention also discloses a novel process for its preparation.Type: ApplicationFiled: August 24, 2011Publication date: January 9, 2014Applicant: SEQUENT SCIENTIFIC LTD.Inventors: Sumangala Venkatramana, Vjesh Alanthatta Madathil, Pejakala Kakrannaya Vasudeva, Thangavel Arulmoli
-
Publication number: 20130317225Abstract: The present invention relates to new rifaximin forms kappa, theta, rifaximin:piperazine cocrystal 1 and rifaximin:piperazine cocrystal 2, methods of making same and to their use in medicinal preparations and therapeutic methods.Type: ApplicationFiled: July 31, 2013Publication date: November 28, 2013Inventors: Yiduo Wu, Stephan D. Parent, Nathan Carl Schultheiss, Melanie Janelle Bevill, Petinka Vlahova, Travis L. Houston
-
Publication number: 20130315998Abstract: A topical foam pharmaceutical composition for rectal administration comprising rifaximin is described. Also described is a method of making the composition and the use of the composition as a medicament.Type: ApplicationFiled: August 5, 2013Publication date: November 28, 2013Applicant: CIPLA LimitedInventors: Amar Lulla, Geena Malhotra
-
Publication number: 20130281697Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.Type: ApplicationFiled: November 19, 2012Publication date: October 24, 2013Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Publication number: 20130217672Abstract: A (+)-3-hydroxymorphinan-based polycycle derivative of formula (I) is effective as a neuroprotective agent for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and ischemic stroke.Type: ApplicationFiled: May 13, 2011Publication date: August 22, 2013Applicant: GREEN CROSS CORPORATIONInventors: Jinhwa Lee, Jong Yup Kim, Jeongmin Kim, Kwang Woo Ahn
-
Publication number: 20130066079Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.Type: ApplicationFiled: August 23, 2012Publication date: March 14, 2013Applicant: Salix Pharmaceuticals, Ltd.Inventors: Karen S. Gushurst, Donglai Yang, Melanie Roe, Nathan Schultheiss, Petinka Vlahova, Jeffrey S. Stults, Travis L. Houston
-
Publication number: 20120289532Abstract: The present invention relates to a new amorphous form of rifaximin and to methods for the preparation thereof by means of high energy milling or Spray drying. The present invention further relates to a new amorphous form for use as medicament and to the pharmaceutical compositions composing it.Type: ApplicationFiled: December 27, 2010Publication date: November 15, 2012Inventors: Silvio Massimo Lavagna, Daniela Secci, Franco Padella
-
Publication number: 20120245355Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.Type: ApplicationFiled: June 4, 2012Publication date: September 27, 2012Applicant: ALFA WASSERMANN, S.P.A.Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Donatella CONFORTINI, Maria Miriam BARBANTI, Dario BRAGA
-
Publication number: 20120203000Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.Type: ApplicationFiled: April 16, 2012Publication date: August 9, 2012Applicant: ALFA WASSERMANN, S.P.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Publication number: 20110300567Abstract: A method for identifying the redox activity of a subject compound is disclosed. The method can be performed aerobically and can include forming a mixture comprising a free-radical precursor and a compound to be tested, and converting the free-radical precursor into a free-radical anion and a free-radical cation. After the free radical cation and the free radical anion have been formed, the relative redox activity of the subject compound may cause a difference in the rate of photo-bleaching of the mixture and/or the rate of superoxide generation. These differences can be quantified and used to identify the redox activity of the subject compound. This sensitive technique for measuring redox activity can be used to screen compounds for various biological applications. Drugs also can be developed based on the relationship between redox activity and biological activity for particular biological applications.Type: ApplicationFiled: August 9, 2011Publication date: December 8, 2011Inventors: Jonathan J. Abramson, Benjamin S. Marinov
-
Publication number: 20110166170Abstract: The syntheses of the natural products, avrainvillamide and stephacidin B, are provided. The ?,?-unsaturated nitrone functionality of avrainvillamide and its 3-alkylidene-3H-indole 1-oxide core is shown to covalently and reversibly bond to heteroatom-based nucleophiles. This capability may allow these molecules to bind active site nucleophiles and may provide the basis for designing potent and selective enzyme inhibitors. Both avrainvillamide and its dimer stephacidin B have been reported to exhibit antiproliferative activity, and avrainvillamide has been reported to exhibit antimicrobial activity against multi-drug resistant bacteria. Avrainvillamide has been found to target cytoskeleton-linking membrane protein (CLIMP-63) thereby preventing cells from undergoing mitosis. The invention provides syntheses of these natural products as well as analogs of these natural products and their functional cores.Type: ApplicationFiled: October 27, 2010Publication date: July 7, 2011Applicant: President and Fellows of Harvard CollegeInventors: Andrew G. Myers, Seth B. Herzon, Jeremy Earle Wulff, Romain Siegrist, Jakub Svenda, Matthew Allen Zajac
-
Patent number: 7951817Abstract: Compounds represented by the formula: wherein R is C1-6 alkyl; C4-6 cycloalkylalkyl; or C3-6 alkenyl; R? is H or C1-6 alkyl; X is H or OH; Y is alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl or aroyl; and Z is CH or N; provided that X is H, when Z is CH and R is C4 cycloalkylalkyl or C4 alkenyl; prodrugs thereof; and pharmaceutically acceptable salts thereof are provided. Compounds of the above formula are useful as analgesics for treating pain; as immunomodulators, to modulate the behavioral effects of drugs of abuse and to modulate the development of tolerance and dependence to ? agonists.Type: GrantFiled: March 19, 2009Date of Patent: May 31, 2011Assignees: The United States of America as represented by the Department of Health and Human Services, Southern Research Institute, University of New England College of Osteopathic Medicine, The Arizona Board of Regents on Behalf of the University of ArizonaInventors: Subramaniam Ananthan, Richard B. Rothman, Edward J. Bilsky, Frank Porreca
-
Publication number: 20110098474Abstract: This invention relates to intermediates useful in the preparation of opiate alkaloids, particularly morphinane compounds. The invention also relates to processes for preparing such intermediates and to processes which utilise such intermediates in the synthesis of morphinane compounds.Type: ApplicationFiled: January 3, 2011Publication date: April 28, 2011Applicants: JOHNSON MATTHEY PUBLIC LIMITED COMPANY, GLAXOSMITHKLINE AUSTRALIA PTY. LTD.Inventors: Craig Smith, Stuart Purcell, Lucy Waddell, Nicholas Hayes, Jarrod Ritchie, Scott Brian Halliday, Melville Mitchell, George Scott Wilson
-
Publication number: 20110055943Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of bowl disease (BD). The invention provides BD-associated polynucleotide sequences whose expression is associated with BD. Provided herein are diagnostic compositions and methods for the detection of BD. The present invention provides monoclonal and polyclonal antibodies specific for the BD polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of BD.Type: ApplicationFiled: October 16, 2008Publication date: March 3, 2011Applicant: SALIX PHARMACEUTICALS, LTD.Inventors: Frank J. Gonzalez, Lorin Johnson, Xiaochao Ma
-
Publication number: 20090312357Abstract: Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.Type: ApplicationFiled: September 24, 2007Publication date: December 17, 2009Applicant: CIPLA LimitedInventors: Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan, Manjinder Singh Phull, Maruti Ghagare
-
Publication number: 20090239892Abstract: Compounds represented by the formula: wherein R is C1-6 alkyl; C4-6 cycloalkylalkyl; or C3-6 alkenyl; R? is H or C1-6 alkyl; X is H or OH; Y is alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl or aroyl; and Z is CH or N; provided that X is H, when Z is CH and R is C4 cycloalkylalkyl or C4 alkenyl; prodrugs thereof; and pharmaceutically acceptable salts thereof are provided. Compounds of the above formula are useful as analgesics for treating pain; as immunomodulators, to modulate the behavioral effects of drugs of abuse and to modulate the development of tolerance and dependence to ? agonists.Type: ApplicationFiled: March 19, 2009Publication date: September 24, 2009Applicants: Southern Research Institute, National Institute on Drug Abuse, National Institute of Health, University of New England College of Osteopathic Medicine, The Arizona Board of Reagents on behalf of the University of ArizonaInventors: Subramaniam Ananthan, Richard B. Rothman, Edward J. Bilsky, Frank Porreca
-
Patent number: 7541364Abstract: Compounds represented by the formula: wherein R is C1-6 alkyl; C4-6 cycloalkylalkyl; or C3-6 alkenyl; R? is H or C1-6 alkyl; X is H or OH; Y is alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl or aroyl; and Z is CH or N; provided that X is H, when Z is CH and R is C4 cycloalkylalkyl or C4 alkenyl; prodrugs thereof; and pharmaceutically acceptable salts thereof are provided. Compounds of the above formula are useful as analgesics for treating pain; as immunomodulators, to modulate the behavioral effects of drugs of abuse and to modulate the development of tolerance and dependence to ? agonists.Type: GrantFiled: August 27, 2004Date of Patent: June 2, 2009Assignee: Southern Research InstituteInventors: Subramaniam Ananthan, Richard B. Rothman, Edward J. Bilsky, Frank Porreca
-
Publication number: 20090130201Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.Type: ApplicationFiled: February 27, 2006Publication date: May 21, 2009Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Donatella Confortini, Maria Miriam Barbanti, Dario Braga
-
Patent number: 7534799Abstract: Compounds represented by the formulae: wherein each of Y, X and R individually is selected from the group consisting of hydrogen, hydroxy, halo, CF3, NO2, CN, NH2, COR1 and CO2R2 wherein R1 is selected from the group consisting of alkyl, aryl, alkaryl, and NH2, and R2 is selected from the group consisting of alkyl, aryl and aralkyl, and provided that at least one of Y, X and R is other than H; and pharmaceutically acceptable salts thereof are provided. Compounds of the above formula are useful as analgesics for treating pain, as immunomodulators and for treating drug abuse.Type: GrantFiled: July 25, 2006Date of Patent: May 19, 2009Assignee: Southern Research InstituteInventor: Subramaniam Ananthan
-
Patent number: 7468438Abstract: The present invention relates to an efficient procedure for the synthesis of deserpidine (Ia), starting from reserpic acid lactone (II) via the intermediate 11-O-demethyl reserpic acid lactone (III).Type: GrantFiled: March 2, 2005Date of Patent: December 23, 2008Assignee: Indena S.p.A.Inventors: Gabriele Fontana, Ezio Bombardelli, Cristian Samori, Eleonora Baldelli, Andrea Guerrini, Arturo Battaglia, Bruno Danieli
-
Publication number: 20080262232Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.Type: ApplicationFiled: May 13, 2008Publication date: October 23, 2008Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Publication number: 20080242864Abstract: The present invention relates to an efficient procedure for the synthesis of deserpidine (Ia), starting from reserpic acid lactone (II) via the intermediate 11-O-demethyl reserpic acid lactone (III).Type: ApplicationFiled: March 2, 2005Publication date: October 2, 2008Inventors: Gabriele Fontana, Ezio Bombardelli, Cristian Samori, Eleonora Baldelli, Andrea Guerrini, Arturo Battaglia, Bruno Danieli
-
Publication number: 20080234306Abstract: Novel N-oxides of 4,5-epoxy-morphinanium analogs are disclosed. Pharmaceutical compositions containing the N-oxides of 4,5-epoxy-morphinanium analogs and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as modulators of opioid receptors.Type: ApplicationFiled: November 21, 2007Publication date: September 25, 2008Applicant: Progenics Pharmaceuticals, Inc.Inventors: Julio Perez, Amy Qi Han, Yakov Rotshteyn, Govindaraj Kumaran
-
Publication number: 20080194568Abstract: Compounds represented by formula (I) wherein R is C1-6cycloalkylalkyl; or C3-6 alkenyl; R? is H or C1-6 alkyl; X is H or OH; Y is alkyl, cycloalkyl, aryl, heteroaryl or aroyl; and Z is CH or N; provided that X is H, when Z is CH and R is C4 cycloalkylalkyl or C4 alkenyl; prodrugs thereof; and pharmaceutically acceptable salts thereof are provided. Compounds of the above formula are useful as analgesics for treating pain; as immunomodulators, to modulate the behavioral effects of drugs of abuse and to modulate the development of tolerance and dependence of ? agonists.Type: ApplicationFiled: August 27, 2004Publication date: August 14, 2008Applicants: Southern Research Institute, National Institute on Drugs Abuse, NIH, University of New England College of Osteopathic Medicine, The Arizona Board of Regents on behalf of the University of ArizonaInventors: Subramaniam Ananthan, Richard B. Rothman, Edward J. Bilsky, Frank Porreca
-
Patent number: 7145010Abstract: Tert-alkylphenoxy-substituted polycyclic compounds of the general formula I where P is a conjugated polycyclic radical which is stable to bases and nucleophiles, optionally bears aryl substituents and contains no group from the group consisting of —CO—NH—CO—, —COOH and —CO—O—CO—; R is C1–C8-alkyl, whose carbon chain may be interrupted by one or more groups selected from the group consisting of —O—, —S—, —NR1—, —CO— and/or —SO2— and which may be monosubstituted or polysubstituted by C1–C6-alkoxy or by a 5- to 7-membered heterocyclic radical which is attached via a nitrogen atom and may contain further heteroatoms and be aromatic; C5–C8-cycloalkyl whose carbon chain may be interrupted by one or more groups selected from the group consisting of —O—, —S—, —NR1—, —CO— and/or —SO2— and which may be monosubstituted or polysubstituted by C1–C6-alkyl; R1 is hydrogen or C1–C6-alkyl; Hal is chlorine and/or bromine; m is from 0 to 15; n is from 1 to 16, subject to the proviso that the sum m+n is ?16, are prepared aType: GrantFiled: March 20, 2002Date of Patent: December 5, 2006Assignee: BASF AktiengesellschaftInventors: Arno Boehm, Willi Helfer, Georg Beck, Matthias Krieger, Peter Erk
-
Patent number: 7105675Abstract: Compounds represented by the formulae: wherein each of Y, X and R individually is selected from the group consisting of hydrogen, hydroxy, halo, CF3, NO2, CN, NH2, COR1 and CO2R2 wherein R1 is selected from the group consisting of alkyl, aryl, alkaryl, and NH2, and R2 is selected from the group consisting of alkyl, aryl and aralkyl, and provided that at least one of Y, X and R is other than H; and pharmaceutically acceptable salts thereof are provided. Compounds of the above formula are useful as analgesics for treating pain, as immunomodulators and for treating drug abuse.Type: GrantFiled: October 27, 2005Date of Patent: September 12, 2006Assignee: Southern Research InstituteInventor: Subramaniam Ananthan
-
Patent number: 7015326Abstract: Compounds represented by the formulae: wherein each of Y, X and R individually is selected from the group consisting of hydrogen hydroxy, halo, CF3, NO2, CN, NH2, COR1 and CO2R2 wherein R1 is selected from the group consisting of alkyl, aryl, alkaryl, and NH2, and R2 is selected from the group consisting of alkyl aryl, and aralkyl, and provided that at least one of Y, X and R in formula I is other than hydrogen; and pharmaceutically acceptable salts thereof are provided along with uses as immunodulaters and/or treating for drug abuse and/or as analegesics for treating pain.Type: GrantFiled: August 14, 2000Date of Patent: March 21, 2006Assignee: Southern Research InstituteInventor: Subramaniam Ananthan
-
Publication number: 20040138451Abstract: The epindolidione compounds of the general formula (I) 1Type: ApplicationFiled: January 22, 2004Publication date: July 15, 2004Inventors: Bansi Lal Kaul, Bruno Piastra, Valerie Wolf, Frank Prokschy, Martin Ulrich Schmidt
-
Publication number: 20040102467Abstract: This invention features ring-substituted pyrrolo-&bgr;-carboline derivatives and ring-substitution and structural derivatives of 3-(1H-indol-3-yl)-1H-pyrrole-2,5-dione of formulas (I-III), which are useful as neuroprotective and anti-proliferative compounds. Also disclosed are methods for the preparation of these compounds, selected biological profiles and uses of these compounds in the treatment of various neurodegenerative and inflammatory diseases of the human nervous system and in the treatment of various other proliferative disorders characterized by loss of growth or cellular differentiation control including, but not limited to, cancer and inflammation.Type: ApplicationFiled: October 23, 2003Publication date: May 27, 2004Inventors: James B Jaquith, Alex Fallis, John W Gillard
-
Publication number: 20030083499Abstract: Compounds represented by the formula: 1Type: ApplicationFiled: April 8, 2002Publication date: May 1, 2003Inventor: Subramaniam Ananthan
-
Patent number: 6465479Abstract: Compounds represented by the formula: wherein each of Y, X and R individually is H, OH, alkyl, alkoxy, aryl, halo, CF3 and NO2, provided that at least one of Y, X and R is other than H; and pharmaceutically acceptable salts thereof are provided. Compounds of the above formula are useful as analgesics for treating pain, as immunomodulators and for treating drug abuse.Type: GrantFiled: August 14, 2000Date of Patent: October 15, 2002Assignee: Southern Research InstituteInventor: Subramaniam Ananthan
-
Patent number: 6365594Abstract: Heterocycle-condensed morphinoid derivatives of formula (I), or solvates or salts thereof, are potent and selective delta opioid agonists and antagonists and are useful as i.a. analgesics. Pharmaceutical compositions containing such compounds, the use of such compounds as therapeutic agents, a method of treatment comprising the administration of such compounds, and a process for the preparation of such compounds are also described.Type: GrantFiled: February 22, 1999Date of Patent: April 2, 2002Assignee: SmithKline Beecham S.p.A.Inventors: Giulio Dondio, Silvano Ronzoni, Pier Andrea Gatti, Davide Graziani
-
Patent number: 6359111Abstract: A compound comprising a ligand portion which has binding affinity for an opioid receptor, and a therapeutically or diagnostically effective group selected from radionuclide chelating agents, fluorochromes, toxins, drugs, polyboron moieties, proteins, biological response modifiers, chemical moieties capable of binding to other molecules of interest, and radioisotopes selected from therapeutically effective alpha and beta emitters, and diagnostically effective gamma emitters. The compound may be used in a method of treating cancer, and in a method of imaging opioid receptors either inside or outside of the central nervous system.Type: GrantFiled: May 27, 1999Date of Patent: March 19, 2002Assignee: NeoRx CorporationInventors: Damon L. Meyer, Sudhakar Kasina
-
Patent number: 6284769Abstract: The compounds of structural formulae (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents, is disclosed. A compound of formula (I) or (II) is an agonist for the &mgr; and &dgr; opioid receptors, an antagonist for the &kgr; opioid receptor, and has high affinity at all three receptors. A compound of formula (I) or (II) has utility in a variety of therapeutic and research areas where &kgr; opioid receptor antagonism is beneficial, including the treatment of opiate addiction or pain, or in a method of stimulating an immune system of a human.Type: GrantFiled: December 3, 1999Date of Patent: September 4, 2001Assignee: The Board of Trustees of the University of IllinoisInventors: William Dunn, Ludwig Bauer, Hemendra N. Bhargava
-
Patent number: 5986099Abstract: Quaterrylenetetracarboxylic diimides I ##STR1## where R is hydrogen;C.sub.1 -C.sub.30 -alkyl whose carbon chain may be interrupted by one or e of --O--, --S--, --NR.sup.1 --, --CO-- and/or --SO.sub.2 -- and which may be monosubstituted or polysubstituted by cyano, C.sub.1 -C.sub.6 -alkoxy or a 5-, 6- or 7-membered heterocyclic radical which is attached via a nitrogen atom and which may contain further heteroatoms and may be aromatic, whereR.sup.1 is hydrogen or C.sub.1 -C.sub.6 -alkyl;C.sub.5 -C.sub.8 -cycloalkyl whose carbon skeleton may be interrupted by one or more of --O--, --S-- and/or --NR.sup.1 --;aryl or hetaryl, which may each be monosubstituted or poly-substituted by C.sub.1 -C.sub.18 -alkyl, C.sub.1 -C.sub.6 -alkoxy, cyano, --CONHR.sup.2, --NHCOR.sup.2 and/or aryl- or hetaryl-azo, which may each be substituted by C.sub.1 -C.sub.10 -alkyl, C.sub.1 -C.sub.6 -alkoxy or cyano, whereR.sup.2 is hydrogen; C.sub.1 -C.sub.18 -alkyl; aryl or hetaryl, which may each be substituted by C.sub.1 -C.sub.Type: GrantFiled: July 21, 1997Date of Patent: November 16, 1999Assignees: BASF Aktiengesellschaft, Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. BerlinInventors: Klaus Mullen, Heribert Quante, Arno Bohm
-
Patent number: 5981540Abstract: Compounds of formula (I), are selective delta opioid agonsist and antagonists, and are useful as analgesics and in treating general neurologic disorders.Type: GrantFiled: April 24, 1997Date of Patent: November 9, 1999Assignee: SmithKline Beecham Farmaceutici S.P.A.Inventors: Giulio Dondio, Silvano Ronzoni
-
Patent number: 5631264Abstract: Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts, pharmaceutical compositions containing them, and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.Type: GrantFiled: May 24, 1995Date of Patent: May 20, 1997Assignee: Sanofi Winthrop, Inc.Inventors: Diane L. DeHaven-Hudkins, John A. Dority, Jr., William G. Earley, Virendra Kumar, John P. Mallamo, Matthew S. Miller, Chakrapani Subramanyam
-
Patent number: 5554620Abstract: Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts, pharmaceutical compositions containing them, and methods for the treatment of neurodegenerative disorders or neurotoxic injuries utilizing them, wherein the substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts have the formula: ##STR1## wherein: R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, X and p are as defined in the specification.Type: GrantFiled: July 29, 1994Date of Patent: September 10, 1996Assignee: Sterling Winthrop Inc.Inventors: Diane L. DeHaven-Hudkins, John A. Dority, Jr., William G. Earley, Virendra Kumar, John P. Mallamo, Matthew S. Miller, Chakrapani Subramanyam
-
Patent number: 4925848Abstract: A compound of the formula: ##STR1## A process for its preparation and pharmaceutical compositions comprising the compound or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable diluent or carrier. The compound exhibits analgesic activity.Type: GrantFiled: April 28, 1988Date of Patent: May 15, 1990Assignee: Reckitt & Colman Products LimitedInventors: John W. Lewis, Colin F. C. Smith
-
Patent number: 4599341Abstract: Novel substituted and bridged pyridine compounds useful as calcium channel blockers, pharmaceutical compositions thereof, and methods of treatment are disclosed.Type: GrantFiled: October 1, 1984Date of Patent: July 8, 1986Assignee: Merck & Co., Inc.Inventors: Wasyl Halczenko, George D. Hartman
-
Patent number: 4587253Abstract: Novel substituted and bridged pyridine compounds useful as calcium channel blockers and analgesics, pharmaceutical compositions thereof, and methods of treatment are disclosed.Type: GrantFiled: July 30, 1984Date of Patent: May 6, 1986Assignee: Merck & Co., Inc.Inventors: Wasyl Halczenko, George D. Hartman
-
Patent number: 4558052Abstract: 10-bromosandwicine and 10-bromoisosandwicine and acid addition salts thereof are disclosed. There novel compounds possess valuable pharmacological properties e.g. heart rhythm regulatory properties. Furthermore they are valuable intermediates for the preparation of 10-brominated N.sub.b -quaternary sandwicine derivatives which exhibit heart rhythm regulatory and adrenolytic properties. 10-bromosandwicine is prepared by brominating sandwicine and can subsequently be isomerized into 10-bromoisosandwicine.Type: GrantFiled: June 8, 1984Date of Patent: December 10, 1985Assignee: Kali-Chemie Pharma GmbHInventors: Wolfgang Kehrbach, Joachim Wegener